Nowadays, substantial evidence supports that the checkpoint inhibitors of SIRPα-CD47 can suppress tumor growth by skewing tumor-associated macrophages toward the M1 phenotype from the M2 phenotype, which restores the phagocytic activities of macrophages [66]. The gene discussed is SIRPA; the disease is neoplasm.